Meeting category
Date(s)
22 May 2024 - 24 May 2024
Program Language
English
Location
Barcelona,
Spain
Meeting type
Hybrid Meeting
CME Credits
9
Organizer
European Meeting on HIV & Hepatitis 2024
Related Enduring Materials
Enduring Materials
Opening Session: HIV Prevention in Europe - State of the Art -
Anna Maria Geretti, MD, PhD, FRCPath
Deniz Gökengin, MD, PhD
Current Implementation of PrEP in EU: Data from the ECDC
The Role of Social and Structural Determinants on Access to PrEP
Resistance Considerations in Choosing PrEP Across Europe
University of Rome, Italy / King's College London, United Kingdom
Prevention of STIs: The Role of Doxy-PEP
Ege University, School of Medicine, Department of Infectious Diseases, Turkey
Session 1: Treatment Considerations -
Weight Gain and ARV Therapy: What a Clinician Needs to Know
Charles Boucher Lecture - Resistance Testing in Routine Care: What a Clinician Needs to Know
Andrea De Luca Lecture - Low Level Viremia: Is It Clinically Relevant?
Guided Poster Tour 1: New Insights in Hepatitis Elimination and New ARV Drugs - Abstract
Abstract #25
Enhancing HDV Diagnostic Algorithm in Israel: Reflex Testing, Prevalence of HDV Seropositive Individuals, and Evaluation of Three HDV Viral Load Assays
Orna Mor
Ministry Of Health and Tel Aviv University, Israel
Abstract #28
Whole Genome Sequencing for Genotyping the Hepatitis Delta Virus
Federico García
Hospital Universitario San Cecilio, Spain
Abstract #43
Additive activity of doravirine and islatravir against NRTI and NNRTI resistant HIV-1 in vitro
Federica Giammarino
Karolinska Institutet, Sweden
Abstract #46
The in vitro genetic barrier to resistance of lenacapavir is not affected by viral subtype or heavy treatment exposure
Niccolò Bartolini
Università degli Studi di Siena, Italy
Abstract #51
Applying next-generation sequencing to track HIV-1 drug resistance mutations circulating in Portugal
Victor Pimentel
Instituto De Higiene E Medicina Tropical, Portugal
Abstract #64
Evaluation of a commercial HIV whole genome kit for HIV-1 sequencing
Nadine Lübke
Institute of Virology, University Hospital Düsseldorf, Germany
Session 2: What Is New in HIV Treatment -
Josep Llibre, MD, PhD
Oana Săndulescu, MD, PhD
Personalized Treatment Regimens
Fundació Lluita contra la Sida; Hospital Universitari Germans Trias i Pujol, Spain
Women's Health Throughout the Life Cycle
Carol Davila University of Medicine and Pharmacy / National Institute for Infectious Diseases "Prof.Dr. Matei Bals", Romania
Session 3: HIV Drug Resistance -
Oral Abstract Presentation #8 - Assessment of integrase resistance mutations in people living with HIV undergoing treatment in Portugal: A two-year (2022-2024) virological failure analysis
Session 4: Respiratory Viruses - Update and Relation to People Living with HIV -
Paul Loubet, MD, PhD, MPH
Diagnostics on Respiratory Viruses / Multiplex Diagnostics
RSV Immunoprophylaxis: Where Are We and What Is the Impact on Viral Genetic Diversity
The Burden of Respiratory Viruses in Immunocompromised People
Infectious Diseases Department, Nîmes University Hospital, Montpellier University, France
Oral Abstract Presentation #17 - Characterization of long Covid-19 and associated factors in people living with HIV: A systematic review and meta-analysis
Guided Poster Tour 2: New Insights in HIV and New ARV Drugs - Abstract
Abstract #38
Long-Acting injectable regimen with Cabotegravir + Rilpivirine in people living with HIV: real-life experience from Modena HIV Clinic
Marianna Menozzi
Aou Policlinico Di Modena, Italy
Abstract #40
Clinical Impact and Prevalence of APOBEC Mutations in Reports of HIV Antiretroviral Resistance
Federico García
Hospital Universitario San Cecilio, Spain
Abstract #44
Natural phenotypic susceptibility of non-group M HIV-1 to DORAVIRINE, a new-generation non-nucleoside reverse transcriptase inhibitor: DORAVI-O study
Boris Derman
CHU Rouen, France
Abstract #62
An evaluation of Next Generation Sequencing for analysis of HIV-1 Capsid sequences
Jannik Fonager
Statens Serum Institut, Denmark
Abstract #74
Efficacy of Dolutegravir (DTG) and Lamivudine (3TC) in Adults With HIV-1 and Isolated Reactive Hepatitis B Core Antibody (Anti-HBc): Results From the Phase 3 GEMINI-1/-2, TANGO, and SALSA Studies
Dainielle Fox
ViiV Healthcare, United States
Abstract #77
Torque Teno Virus load is associated with CDC stage and CD4+ cell count in people living with HIV but unrelated to AIDS-defining events and Human Pegivirus load
Martin Pirkl
University Hospital Cologne, Germany
Session 5: Evolving Challenges in HIV Care -
Anca Streinu-Cercel, MD, PhD
Migration and Its Impact on the Epidemiology of HIV in Europe
HIV Care in Migrant Populations
Addressing Late HIV Presentation: A Stubborn Unmet Need
National Institute of Infectious Diseases "Prof. Dr. Matei Bals", Romania
Oral Abstract Presentation #21 - Updates on the clinical epidemiology of HIV-1 group O strains in Cameroon and potential implications on diagnosis and treatment strategies
Debate: Clinical Value of Proviral DNA Resistance Testing
Session 6: What's in the Pipeline? Presentations on Future Viral Therapeutics and Vaccines from Scientists from Industry (non-CME) - 11:30
11:30 CEST
The full program of "Session 6: What is in the Pipeline?" can be visited in the "Industry Program" Tab when available
Session 7: Viral Hepatitis - What’s New in Prevention and Treatment (HBV, HCV, HDV) -
Christopher Dietz-Fricke, MD
Innovative Diagnostic Strategies and Markers in HBV and HDV
New Drugs for HBV & HDV: State of the Art
Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy / Dept. of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Germany
Acute HCV and Reinfection
Oral Abstract Presentation #24 - ENABLING ACCESS TO HCV CARE THROUGH COMMUNITY-BASED PROGRAMMING DURING THE ACTIVE WAR PERIOD FOR THE PEOPLE LIVING WITH HIV IN UKRAINE
Industry Program
Session 6: What's in the Pipeline? Presentations on Future Viral Therapeutics and Vaccines from Scientists from Industry -
Calvin Cohen, MD, MSc
Harmony Garges, MD, MPH
Update on the GS HIV Pipeline: A Focus on Treatment and Prevention
Executive Director, Global HIV Medical Affairs, Gilead Sciences, United States
Today and Tomorrow's HIV Treatments and Prevention Therapies: It's All About Long-Acting!
Senior Vice President, Chief Medical Officer and Head of Global Medical, ViiV Healthcare, United States
Update on the MSD HIV Pipeline: Prevention, Treatment, and Cure
Overview
Welcome
The 22nd Edition of the European Meeting on HIV & Hepatitis took place as a hybrid meeting from 22-24 May 2024 in Barcelona, Spain.
Founded more than twenty years ago as the European HIV Resistance Workshop, the European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance has evolved to embrace all aspects of the clinical care of people living with HIV in Europe. This workshop places emphasis in particular on optimal treatment strategies, clinical virology, molecular epidemiology, and public health aspects of HIV, HBV, HCV, as well as emerging viruses throughout Europe.
In the last decade, the meeting has been able to capture leading clinicians and researchers from different regions of Europe. As such, this meeting is the only European platform where HIV-treating physicians and clinical virologists get together on an annual basis to present their latest research results and discuss their clinical implications in detail.
General Information
Who Should Attend?
Primary: Europe-based clinicians/physicians and researchers involved in the fields of HIV, HBV, and HCV.
Secondary: Laboratory managers, technicians, pharmacists, and pharmacologists.
- Residents, post-graduates, and PhD students
- Government agency personnel, NGO representatives, and health authority personnel
- Industry representatives
- Social workers, advocates, and community workers
- Other healthcare professionals involved in treating HIV and co-infected patients
Secondary: Laboratory managers, technicians, pharmacists, and pharmacologists.
- Residents, post-graduates, and PhD students
- Government agency personnel, NGO representatives, and health authority personnel
- Industry representatives
- Social workers, advocates, and community workers
- Other healthcare professionals involved in treating HIV and co-infected patients
Meeting Objectives
This meeting aims to:
- Gather professionals in the fields of HIV and hepatitis clinical care and research in an interactive workshop setting;
- Provide a platform for presentation and discussion of the latest developments in the field of antiviral drug development;
- Map important current studies and results;
- Translate new data into treatment guidelines; and
- Educate clinicians on how to best implement current and new drugs in clinical practice.
- Gather professionals in the fields of HIV and hepatitis clinical care and research in an interactive workshop setting;
- Provide a platform for presentation and discussion of the latest developments in the field of antiviral drug development;
- Map important current studies and results;
- Translate new data into treatment guidelines; and
- Educate clinicians on how to best implement current and new drugs in clinical practice.
Learning Objectives
After participating in this activity, participants will be able to:
- Summarize recent results (including clinical trial results) in drug development for HIV or Hepatitis.
- Apply the latest scientific results into daily clinical care to improve the quality of life of individuals living with HIV.
- Identify future challenges in the screening, monitoring and diagnosis of patients living with HIV or Hepatitis and develop new concepts for research and care strategies.
- Summarize recent results (including clinical trial results) in drug development for HIV or Hepatitis.
- Apply the latest scientific results into daily clinical care to improve the quality of life of individuals living with HIV.
- Identify future challenges in the screening, monitoring and diagnosis of patients living with HIV or Hepatitis and develop new concepts for research and care strategies.
Practical Information
Ethical MedTech
We are glad to inform that the European Meeting on HIV & Hepatitis 2024 has received COMPLIANT status from Ethical MedTech Europe platform.
For more information, you can visit the website of Ethical MedTech EU with the following link: https://www.ethicalmedtech.eu/
For more information, you can visit the website of Ethical MedTech EU with the following link: https://www.ethicalmedtech.eu/
Venue
The confirmed venue for the European Meeting on HIV & Hepatitis 2024 is at the following location:
Hotel Catalonia Barcelona Plaza
Pl. d'Espanya, 8, Sants-Montjuïc
08014 Barcelona
Spain
Distance from Barcelona Airport (BCN): 13 km
Hotel Catalonia Barcelona Plaza
Pl. d'Espanya, 8, Sants-Montjuïc
08014 Barcelona
Spain
Distance from Barcelona Airport (BCN): 13 km
Badges
All participants are requested to wear the badge at all times during the conference to ensure admission to the meeting.
Certificate of Attendance
A certificate of attendance will be sent to you after successfully completing the program and post-meeting survey.
Language
The official language of the meeting is English. Translation is not provided.
Conference Materials
The meeting materials can be obtained upon registration at the registration desk at the venue.
Disclaimer
This conference is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this event, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this meeting. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the conference.
Liability and Insurance
By registering for the conference participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.
Photographs, Audio, and Video Recording
Photographs, audio, and video recordings are not permitted at the official meeting sessions. Only the official medical writer appointed by the organization may make recordings. All presentations will be posted here as soon as possible after the workshop is finished, provided the speaker has given permission to do so.
Code of Conduct
All attendees, speakers, co-organizers, partners, endorsers, suppliers, volunteers, and employees at any of our programs are expected to observe our Code of Conduct. We cannot tolerate any form of discrimination, harassment, disrespect, or the marginalization of those involved in our programs. All participants of VE and AME-organized programs are expected to treat others with dignity and respect at all times.
Any individual who feels discriminated against, harassed, disrespected, or marginalized is encouraged to report the incident(s) to VE and AME via info@amededu.com or to one of our on-site personnel.
Any participant who is found to have exhibited any inappropriate conduct or behavior against others may be removed from the program.
Any individual who feels discriminated against, harassed, disrespected, or marginalized is encouraged to report the incident(s) to VE and AME via info@amededu.com or to one of our on-site personnel.
Any participant who is found to have exhibited any inappropriate conduct or behavior against others may be removed from the program.
Committees
Program Chairs
Organizing Committee
The members of the Organizing Committee are a group of carefully selected experts and inspirational leaders in their respective fields. They meet frequently to discuss the scientific program of the workshop, identify interesting topics and candidate speakers, and review all submitted abstracts.
Scientific Program Coordinator
Scientific Committee
The members of Scientific Committee are hand-picked by the Organizing Committee and the conference secretariat based on their significant contributions and commitment to the field. They assist the Organizing Committee by providing them with suggestions for speakers and topics. In addition, they participate in reviewing submitted abstracts, and play an active role during the workshop as moderators and/or chairs of sessions.
-
Ana B. Abecasis, MD, PhD, PharmD - Global Health and Tropical Medicine, Institute of Hygiene and Tropical Medicine, Universidade NOVA de Lisboa, Portugal
-
Marina Bobkova, PhD - Ivanovsky Institute of Virology, Russia
-
Stéphane Chevaliez, PharmD, PhD - University of Paris-Est Creteil, France
-
Federico García, PharmD, PhD - Hospital Universitario San Cecilio, Spain
-
Rolf Kaiser, PhD - University of Cologne, Germany
-
Leon Kostrikis, PhD - University of Cyprus, Cyprus
-
Clive Loveday, PhD - ICVC Charitable Trust, Clinical Virology, United Kingdom
-
Anne-Geneviève Marcelin, MD - Hôpital Pitié-Salpétrière Paris, France
-
Monique Nijhuis, PhD - University Medical Centre Utrecht, the Netherlands
-
Roger Paredes, MD, PhD - IrsiCaixa AIDS Research Institute, Spain
-
Mario Poljak, MD, PhD - Institute for Microbiology and Immunology, Slovenia
-
Gary Rubin, MD - University of Toronto, Canada
-
Anne–Mieke Vandamme, PhD - University of Leuven, Belgium
- Maria Santoro, MD - University of Rome "Tor Vergata", Italy
-
Anders Sönnerborg, MD, PhD - Karolinska Institute, Sweden
-
Janusz Stanczak, PhD - University of Warsaw, Poland
-
Jens Verheyen, MD, PhD - Institute of Immunology and Genetics, Germany
-
David van de Vijver, PharmD, PhD - Erasmus University Rotterdam, the Netherlands
-
Hauke Walter, MD - Medizinisches Labor Stendhal, Germany
-
Annemarie Wensing, MD, PhD - University Medical Center Utrecht, the Netherlands
-
Maurizio Zazzi, PhD - University of Siena, Italy
Accreditation
EACCME® Accreditation Statement
European Meeting on HIV & Hepatitis 2024, Barcelona, Spain, 22/05/2024 - 24/05/2024 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 9 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credits to AMA credits can be found at https://edhub.ama-assn.org/pages/applications.
Live educational activities occurring outside of Canada, recognized by the UEMS-EACCME® for ECMEC® credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.
Endorsers
Endorsers
BCN checkpoint
HIVPA
Support
Platinum Level
Support provided by ViiV Healthcare.
Silver Level
Supported by Gilead who provided funding. Gilead has had no input into the content of the materials used at this meeting.
Support Our Initiative
Financial backing to the European Meeting on HIV & Hepatitis 2024 helps us deliver an impactful meeting experience to the benefit of healthcare professionals and researchers interested in HIV & Hepatitis in the European region.
This collaboration plays a vital role in both the organizational as well as scientific success of the program.
To show your commitment to the cause, get in touch with us for a tailored support package by contacting Jesper Niesen at Jesper.Niesen@amededu.com or call +31 30 230 7140.
Benefits of Support
By supporting this program, we can offer the following advantages for your company.* Please contact us for the most recent support level benefits for this program.
- Symposium opportunities
- Non-commercial interviews with company representatives
- Verbal acknowledgement during the program
- Discounted and complimentary registrations for your representatives
- Company acknowledgement on digital meeting materials including but not limited to newsletters, flyers, the streaming platform, and our website
- Company acknowledgement on printed meeting materials including but not limited to banners and the program book
- Digital and printed advertising opportunities
- Social media shout-outs
- Logo on the conference bag
*Subject to the support level.
Media
Group Photo
Image
5 Key Takeaway Messages
We are excited to share 5 key takeaways from the meeting, curated by our esteemed Program Chair, Dr. Josep Llibre.
Image
|
Hot debate on Proviral DNA resistance testing. If the clinician has a situation where he/she believes that DNA genotype resistance testing could be useful, if it is properly informed and results are discussed together with the virologist, it might have a role and should be considered. The main role of the virologist is to separate the 18 most frequent APOBEC-induced mutations that might not have a clinical implication and could confuse the clinician. These hypermutations are usually associated with defective proviral genomes and their removal is essential in the interpretation of these tests. |
|
Drug-resistance mutations (DRM) are not necessarily archived forever. Despite the plausible biological hypothesis that once a DRM has been selected it will theoretically persist forever in the HIV reservoir, it has been proven that while plasma HIV-RNA suppression goes on, the percentage of HIV clones with resistance wanes and it can even become undetectable. This has been proven with M184V but in this meeting we learned that integrase strand transfer resistance mutations experience a progressive clearance as well in PWH with persistent virological suppression. These mutations were no longer detectable by Sanger sequencing in 90% of the participants, and in 85% by UDS at 3-5 years. |
|
The best technical cut-off for next generation sequencing is 5%. Next-generation sequencing can technically detect variants with a prevalence as low as 0.1%. The 5% threshold has an acceptable sequence accuracy and has been proven useful to improve prediction of drug activity and virological rebound. Similarly, it reduces the reporting of errors and artefacts and has the higher consistency agreement with Sanger results. Whole genome sequencing will become probably the next tool when it becomes available in the clinic. |
|
We must close all the doors to potential HIV resistance selection. These include transmitted HIV resistance, rates of people with multidrug resistance and limited treatment options, resistance selected upon ART failure, and the resistance selected in low-middle income countries, particularly against dolutegravir. All these doors can potentially jeopardise the efficacy of the amazing treatments we currently have. Using drugs with a high resistance barrier is the best way to preserve ART efficacy, has important clinical implications, and maintains U=U, a potent weapon to fight HIV-associated stigma. |
|
Low-level HIV viremia is still relevant. It is associated with higher initial plasma HIV-RNA and lower CD4 at baseline, therefore suggesting a relationship with a higher size of HIV reservoirs. It is seen in approximately 2-5% at 48 weeks of PWH, when properly defined as 50-199 HIV-RNA copies/mL. In many cases, it seems associated with clonal expansion of incomplete or replication incompetent HIV clones, but in a subset of individuals it can increase the risk of virological failure and resistance selection, particularly if subjects are receiving regimens with a low resistance barrier. Anyway, defective pro-viruses are not inert. They can produce viral products that may contribute to persistent immune activation. PWH treated with integrase inhibitor-based regimens have similar rates of low-level viremia, suggesting that this complication is independent of the ART regimen. |
Invitation to Join the 2024 Meeting
Previous Editions
Previous Editions
-
21st Edition - European Meeting on HIV & Hepatitis, 2023, Italy
-
20th Edition - European Meeting on HIV & Hepatitis, 2022, France (Hybrid)
-
19th Edition - European Meeting on HIV & Hepatitis, 2021, Virtual
-
18th Edition - European Meeting on HIV & Hepatitis, 2020, Virtual
-
17th Edition - European Meeting on HIV & Hepatitis, 2019, Italy
-
16th Edition - European Meeting on HIV & Hepatitis, 2018, Italy
-
14th Edition - European Meeting on HIV & Hepatitis, 2016, Italy
Language
Related Programs
